Alan Schwebel - Bio View CEO and Pres

All Insiders . Israel . 
Stock . Bio View . Stakeholders . Insider . Alan Schwebel
BIOV Stock  ILS 25.30  0.90  3.44%   

CEO

Dr. Alan Schwebel serves as Chief Executive Officer and Director at Bio View Ltd since March 19, 2009. Previously, he served as Vice President of Sales and Marketing at the Company from May 12, 2002 until March 19, 2009. Dr. Schwebel has more than 20 years of experience in senior management positions in Medical Device and Medical Diagnostic Companies. Prior to joining the Company, he served as President of Mennen Medical Ltd., a medical device company since 2009.
Age 69
Tenure 15 years
Professional MarksPh.D
Phone972 73 227 1025
Webhttps://www.bioview.com
Schwebel holds a Doctorate of Science degree in Chemistry from City University of New York and a B.Sc. degree in Chemistry from the City University of New York at Brooklyn College.

Bio View Management Efficiency

Bio View's management efficiency ratios could be used to measure how well Bio View manages its routine affairs as well as how well it operates its assets and liabilities.
Bio View has accumulated 2.57 M in total debt with debt to equity ratio (D/E) of 11.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Bio View has a current ratio of 2.1, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Bio View until it has trouble settling it off, either with new capital or with free cash flow. So, Bio View's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bio View sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bio to invest in growth at high rates of return. When we think about Bio View's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 2 records

CEO Age

Ran GuronBezeq Israeli Telecommunication
55
David MizrahiBezeq Israeli Telecommunication
53
BioView Ltd. develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company was founded in 2000 and is headquartered in Rehovot, Israel. BIO VIEW is traded on Tel Aviv Stock Exchange in Israel. Bio View (BIOV) is traded on Tel Aviv Stock Exchange in Israel and employs 35 people.

Management Performance

Return On Equity0.0399
Return On Asset0.0091

Bio View Leadership Team

Elected by the shareholders, the Bio View's board of directors comprises two types of representatives: Bio View inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio View's management team and ensure that shareholders' interests are well served. Bio View's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio View's outside directors are responsible for providing unbiased perspectives on the board's policies.
Alan Schwebel, CEO and Pres
Elad Kfir, Vice President of Marketing
Yulia CPA, Chief Officer
Inbal Hillel, Vice President - Operations
Yuval MSc, Ex VP
David Kutas, CEO of BioView Inc - USA and President of BioView Inc - USA

Bio Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio View a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0399
Return On Asset0.0091
Profit Margin0.04 %
Operating Margin0.02 %
Current Valuation35.4 M
Shares Outstanding13.75 M
Shares Owned By Insiders51.58 %
Price To Book1.72 X
Price To Sales1.71 X
Revenue30.51 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Other Information on Investing in Bio Stock

Bio View financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio View security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY